mardi 22 septembre 2020

Evaluate Ltd: Small Drug Developers Continue to Hold All the Cards, While Young Device Makers Suffer from a Shrinking Pool of Buyers

Par Rédaction , dans Communiqués , le 20 août 2018

Monday, August 20th 2018 at 8:13am UTC

Vantage releases its half-year analysis of sector performance:
Pharma, Biotech and Medtech Half-Year Review 2018

LONDON & BOSTON & TOKYO–(BUSINESS WIRE)– The first half of 2018 has seen biopharma IPOs and venture financing
accelerate from the already-healthy levels witnessed in 2017. Deal
making has dimmed further, however, raising concern that overheated
valuations in certain pockets of the sector are putting off buyers.

Meanwhile, despite the US FDA being on track for another strong year of
approvals, several big biotech and pharma companies are under
considerable pressure to rebuild their pipelines and replace ageing

The situation is reversed somewhat in medtech, where life is harder for
young device makers: a worsening reimbursement climate has put off
investors and a wave of megamergers among big cap medtechs has shrunk
the pool of buyers.

These findings and more were released today as part of the Pharma,
Biotech and Medtech Half-year Review 2018 report by Vantage – formerly
EP Vantage – the editorial arm of commercial intelligence firm Evaluate.

“A very strong funding climate for young drug makers, coupled with a
co-operative US regulator, is creating a lot of excitement in the small
and mid-cap space in biopharma,” said Amy Brown, author of the pharma
and biotech section. “Larger drug makers are desperate for innovation,
however, which is becoming increasingly expensive to buy – a quandary
that should concern executives and investors as 2018 progresses.”

“Smaller medtech companies are having difficulty finding buyers thanks
to consolidation, and venture cash is also hard to come by,” said
Elizabeth Cairns, author of the medtech portion of the report.
“Mid-stage groups have no choice but to turn to the public markets for
growth capital, explaining the surge in IPOs.” Other key findings from
the first half of 2018 include:

  • Big biotech and big pharma stocks were largely shunned by investors
  • Demand for new biotech issues shows no sign of flagging, with a record
    $3.5bn raised in IPOs across western stock exchanges
  • Venture financing continues to set records – more than $4bn was raised
    by private drug makers in both the first and second quarters
  • Spending on biotech and pharma M&A looks set to surpass 2017, although
    this is largely down to the $64bn takeout of Shire by Takeda
  • 2018 is shaping up to have the lowest spend on medical device M&A
    since 2013. The total disclosed spend was less than $12bn, compared
    with $48.8bn a year ago.
  • Venture funds pumped $3.3bn into private medtech groups, across just
    90 rounds.
  • 10 medical device companies floated, meaning 2018 is already close to
    the full-year totals for both 2017 and 2016.

The report published today offers analysis and expert commentary on M&A
deals, venture financing, initial public offerings and FDA approvals in
the pharma and medtech sectors during the first a half of 2018. The
report is based on EvaluatePharma® and EvaluateMedTech® data. Download
the full report at


About Vantage

Vantage, formerly known as EP Vantage, provides award-winning,
thought-provoking news and insights into current and future developments
in the industry, and is the only pharmaceutical news service underpinned
by Evaluate’s commercial intelligence. Visit
for free access to daily, data-driven news for pharma, biotech, and

On Twitter: @Vantageanalysis.

About Evaluate Ltd

Evaluate provides trusted commercial intelligence for the pharmaceutical
and medical device industries. Our EvaluatePharma® online subscription
service provides a seamless view of the past, present and future of the
global pharmaceutical market in a single, standardised platform.

Evaluate has been a trusted partner to industry-leading organisations
for over 20 years. For more information on how we give our clients the
time and understanding to drive better decisions, visit us at

On Twitter: @EvaluatePharma,


Evaluate and Vantage (for general questions and U.S. media)
+1 617-936-7783
Partners (for non-U.S. media)
Gemma Harris
+44 (0) 20 7457 2020

Source: Evaluate Ltd

Étiquettes :